Emmaus Life Sciences Inc. has ripped up its European filing of Xyndari, which is approved in the US, after the continent's regulators once again recommended against approving the sickle cell drug.
The US firm, which was delisted from the NASDAQ last week, has announced the withdrawal of its marketing authorization application to the European Medicines Agency for Xyndari, a prescription grade version of the amino acid supplement L-glutamine, for the treatment of sickle cell disease
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?